Table 2. Expression alteration of 37 lincRNAs in discovery and replication stages.
| Ensembl ID | Symbol | Discovery stagea |
Replication Stageb |
Replication Stagec |
|||
|---|---|---|---|---|---|---|---|
| Log2-FCd | P | Log2-FCd | P | Log2-FCd | P | ||
| ENSG00000261039 | RP11-417E7 | 7.04 | 1.47E-08 | 3.49 | 2.42E-03 | 7.11 | 6.45E-05 |
| ENSG00000230838 | AC093850 | 5.84 | 6.87E-08 | 9.72 | 1.19E-10 | 15.03 | 1.42E-11 |
| ENSG00000224577 | AC017048 | 3.26 | 4.31E-05 | 2.17 | 2.69E-02 | 1.03 | 4.56E-01 |
| ENSG00000253364 | RP11-731F5 | 2.52 | 4.88E-03 | 9.31 | 1.78E-09 | 13.17 | 1.16E-08 |
| ENSG00000197308 | GATA3-AS1 | 2.49 | 2.08E-05 | 8.27 | 6.36E-07 | 5.58 | 1.43E-02 |
| ENSG00000259093 | RP11-1112J20 | 2.20 | 6.87E-08 | 2.02 | 8.65E-07 | 2.78 | 4.02E-06 |
| ENSG00000230615 | RP5-1198O20 | 1.72 | 2.80E-04 | 6.53 | 1.75E-13 | 7.58 | 3.50E-09 |
| ENSG00000253161 | RP11-150O12 | 1.68 | 1.00E-03 | 4.61 | 4.12E-05 | 5.54 | 9.67E-04 |
| ENSG00000245750 | RP11-279F6 | 1.57 | 1.17E-03 | 4.96 | 1.63E-04 | 6.07 | 1.47E-03 |
| ENSG00000214548 | MEG3 | −1.17 | 2.47E-07 | −2.35 | 1.15E-07 | −0.75 | 2.18E-01 |
| ENSG00000237697 | LINC00312 | −1.18 | 9.13E-03 | −3.10 | 1.24E-04 | 0.41 | 7.27E-01 |
| ENSG00000267519 | CTD-3252C9 | −1.48 | 6.89E-11 | −1.01 | 4.12E-05 | 1.33 | 2.00E-05 |
| ENSG00000267272 | RP5-1052I5 | −1.56 | 2.64E-05 | −3.02 | 2.65E-04 | −2.37 | 3.67E-02 |
| ENSG00000255455 | RP11-890B15 | −1.62 | 1.28E-04 | −1.59 | 3.60E-04 | −1.35 | 3.52E-02 |
| ENSG00000234076 | TPRG1-AS1 | −1.74 | 3.52E-03 | −1.93 | 1.12E-03 | −3.37 | 2.06E-05 |
| ENSG00000262728 | AC123768 | −1.82 | 4.90E-08 | −1.58 | 1.27E-02 | −3.01 | 2.80E-04 |
| ENSG00000269930 | RP11-932O9 | −1.85 | 9.95E-07 | −1.82 | 8.56E-05 | −1.74 | 7.45E-03 |
| ENSG00000260025 | RP11-490M8 | −2.15 | 1.10E-06 | −1.99 | 1.18E-02 | −2.78 | 6.05E-03 |
| ENSG00000260807 | RP11-161M6 | −2.24 | 1.64E-06 | −1.96 | 4.49E-02 | −5.65 | 1.34E-05 |
| ENSG00000231246 | RP5-965F6 | −2.32 | 4.87E-07 | −3.42 | 5.22E-03 | −2.94 | 7.71E-02 |
| ENSG00000266176 | RP11-855A2 | −2.39 | 9.44E-04 | −4.16 | 9.90E-05 | 0.16 | 9.21E-01 |
| ENSG00000260693 | AC026150 | −2.44 | 1.08E-06 | −1.81 | 3.04E-04 | −1.19 | 8.99E-02 |
| ENSG00000223477 | LINC00842 | −2.46 | 8.86E-08 | −2.93 | 7.21E-04 | −5.50 | 1.07E-06 |
| ENSG00000182021 | RP11-381O7 | −2.57 | 2.33E-05 | −3.26 | 1.17E-06 | −3.67 | 8.14E-05 |
| ENSG00000258498 | DIO3OS | −2.68 | 1.01E-04 | −3.34 | 2.49E-05 | −3.76 | 9.62E-05 |
| ENSG00000269936 | MIR145 | −2.70 | 9.87E-13 | −1.34 | 5.52E-04 | −1.61 | 1.80E-03 |
| ENSG00000229645 | LINC00341 | −2.77 | 6.89E-11 | −3.89 | 7.12E-06 | −2.82 | 1.50E-02 |
| ENSG00000261064 | RP11-1000B6 | −2.79 | 9.95E-07 | −1.33 | 7.23E-03 | −1.77 | 6.81E-03 |
| ENSG00000229108 | AC005550 | −2.81 | 2.28E-05 | −4.31 | 4.11E-04 | −6.34 | 7.85E-05 |
| ENSG00000267194 | RP1-193H18 | −2.81 | 2.97E-06 | −2.32 | 1.43E-03 | −3.05 | 7.26E-04 |
| ENSG00000260124 | RP4-791K14 | −2.84 | 8.18E-06 | −1.84 | 8.56E-06 | −2.32 | 4.72E-05 |
| ENSG00000224307 | RP11-344B5 | −3.10 | 7.24E-04 | −2.07 | 2.87E-03 | −1.88 | 3.44E-02 |
| ENSG00000178947 | LINC00086 | −3.23 | 1.94E-09 | −1.59 | 2.60E-02 | −2.66 | 5.14E-03 |
| ENSG00000259070 | LINC00639 | −3.45 | 2.88E-07 | −2.30 | 8.87E-04 | −3.48 | 1.40E-04 |
| ENSG00000271239 | RP11-238F2 | −3.67 | 3.37E-06 | −3.19 | 3.08E-02 | −3.86 | 5.24E-02 |
| ENSG00000262179 | RP1-302G2 | −4.26 | 6.95E-07 | −5.21 | 3.39E-06 | −4.74 | 1.56E-03 |
| ENSG00000246430 | RP11-16M8 | −5.25 | 2.61E-06 | −6.36 | 4.27E-09 | −3.19 | 3.97E-02 |
aThe discovery stage from TCGA.
b,cThe replication stage from an independent study; bcomparison between paired tumor and adjacent normal breast tissue from cancer patients; ccomparison between tumor and normal breast tissue from healthy controls.
dLog2-FC denotes log2-transformed fold change between breast tumor and non-tumor samples.